 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for NR5A2 |
 Gene summary |
| Basic gene information | Gene symbol | NR5A2 |
| Gene name | nuclear receptor subfamily 5, group A, member 2 | |
| Synonyms | B1F|B1F2|CPF|FTF|FTZ-F1|FTZ-F1beta|LRH-1|LRH1|hB1F-2 | |
| Cytomap | UCSC genome browser: 1q32.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001276464.1, NM_003822.4,NM_205860.2, | |
| Description | CYP7A promoter-binding factoralpha-1-fetoprotein transcription factorb1-binding factor, hepatocyte transcription factor which activates enhancer II of hepatitis B virusfetoprotein-alpha 1 (AFP) transcription factorhepatocytic transcription factor hB1F | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 604453 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000116833 | ||
| HPRD : 06830 | ||
| Vega : OTTHUMG00000035635 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_NR5A2 | |
| BioGPS: 2494 | ||
| Pathway | NCI Pathway Interaction Database: NR5A2 | |
| KEGG: NR5A2 | ||
| REACTOME: NR5A2 | ||
| Pathway Commons: NR5A2 | ||
| Context | iHOP: NR5A2 | |
| ligand binding site mutation search in PubMed: NR5A2 | ||
| UCL Cancer Institute: NR5A2 | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | LiverPancreas | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | LIHCPAAD | |
| Reference showing the relevant tissue of NR5A2 | ||
| Description by TissGene annotations | Have significant anti-correlated miRNA | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID | GO:0006355 | regulation of transcription, DNA-templated | 15723037 | GO:0045070 | positive regulation of viral genome replication | 19264593 | GO:0045893 | positive regulation of transcription, DNA-templated | 15143342 | GO:0006355 | regulation of transcription, DNA-templated | 15723037 | GO:0045070 | positive regulation of viral genome replication | 19264593 | GO:0045893 | positive regulation of transcription, DNA-templated | 15143342 |
| Top |
| TissGeneExp for NR5A2 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| COAD | 1.928010037 | 4.566752345 | -2.638742308 | 2.32E-13 | 7.26E-12 |
| KIRC | 2.365239951 | 0.703338563 | 1.661901389 | 9.15E-20 | 7.02E-19 |
| LUSC | 0.033713808 | 2.163804004 | -2.130090196 | 4.16E-18 | 3.84E-17 |
| BRCA | 1.050122992 | 2.475685273 | -1.425562281 | 3.12E-27 | 3.46E-26 |
| BLCA | -0.256019113 | 1.098991413 | -1.355010526 | 0.00193 | 0.012334253 |
| LIHC | 4.536369729 | 5.540333729 | -1.003964 | 0.00052 | 0.001503802 |
| Top |
| TissGene-miRNA for NR5A2 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| UCS | hsa-miR-125a-5p | MIMAT0000443 | 0.029 | -0.29 | 56 |
| UCS | hsa-miR-219a-5p | MIMAT0000276 | 0.027 | -0.3 | 56 |
| ESCA | hsa-miR-153-3p | MIMAT0000439 | 0.0000029 | -0.33 | 192 |
| ESCA | hsa-miR-153-3p | MIMAT0000439 | 0.0000029 | -0.33 | 192 |
| ESCA | hsa-miR-153-3p | MIMAT0000439 | 0.0000029 | -0.33 | 192 |
| Top |
| TissGeneMut for NR5A2 |
| TissGeneSNV for NR5A2 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.R439C | SKCM | 3 |
| p.E80K | CESC | 2 |
| p.D9N | SKCM | 2 |
| p.D525N | SKCM | 2 |
| p.N439Y | SKCM | 2 |
| p.C103W | LUAD | 1 |
| p.I209T | COAD | 1 |
| p.E224V | SKCM | 1 |
| p.N355H | SKCM | 1 |
| p.G57W | LUAD | 1 |
| p.K462N | COAD | 1 |
| p.D389N | READ | 1 |
| p.E471Q | HNSC | 1 |
| p.L329M | SKCM | 1 |
| p.G253D | UCEC | 1 |
| p.S355P | SKCM | 1 |
| p.D275N | LUSC | 1 |
| p.A219V | UCEC | 1 |
| p.Q144* | SKCM | 1 |
| p.S197F | SKCM | 1 |
| p.E312Q | BLCA | 1 |
| p.K31M | SKCM | 1 |
| p.Q327K | LUSC | 1 |
| p.G262V | LUAD | 1 |
| p.K170M | STAD | 1 |
| p.R439H | STAD | 1 |
| p.A479V | HNSC | 1 |
| p.L185H | BRCA | 1 |
| p.H430R | READ | 1 |
| p.R162H | LGG | 1 |
| p.E368* | UCEC | 1 |
| p.Q115H | LUAD | 1 |
| p.T162K | LGG | 1 |
| p.S292T | GBM | 1 |
| p.L393X | SKCM | 1 |
| p.G222S | SKCM | 1 |
| p.R174T | ESCA | 1 |
| p.Q61H | LUAD | 1 |
| p.K243M | SKCM | 1 |
| p.T208I | UCEC | 1 |
| p.C28S | ACC | 1 |
| p.R142H | HNSC | 1 |
| p.Q181H | UCEC | 1 |
| p.L501F | SKCM | 1 |
| p.G164E | BLCA | 1 |
| p.R28P | ACC | 1 |
| p.S243F | SKCM | 1 |
| p.T202I | ESCA | 1 |
| p.H108N | SKCM | 1 |
| p.P170L | STAD | 1 |
| p.V9M | SKCM | 1 |
| p.H252Y | BLCA | 1 |
| p.T412R | SKCM | 1 |
| p.G421R | ESCA | 1 |
| p.G164E | SKCM | 1 |
| p.G262F | LUAD | 1 |
| p.E505K | SKCM | 1 |
| p.K334I | ESCA | 1 |
| p.R357S | UCS | 1 |
| p.N424Y | ESCA | 1 |
| p.R393Q | SKCM | 1 |
| p.G421R | LUAD | 1 |
| p.E542D | STAD | 1 |
| p.H252Y | BRCA | 1 |
| p.M20L | LIHC | 1 |
| p.E505K | UCEC | 1 |
| p.R142H | UCEC | 1 |
| p.R112Q | SKCM | 1 |
| p.N226Y | LUAD | 1 |
| p.D412G | SKCM | 1 |
| p.A177D | LUSC | 1 |
| p.L339V | BLCA | 1 |
| p.Q410K | LUAD | 1 |
| p.X421K | ESCA | 1 |
| p.A202V | ESCA | 1 |
| p.R439C | UCEC | 1 |
| p.L100I | LUAD | 1 |
| p.L18R | UCEC | 1 |
| p.D91N | ESCA | 1 |
| p.R160K | LIHC | 1 |
| p.K501X | SKCM | 1 |
| p.R439H | SKCM | 1 |
| p.E272Q | BLCA | 1 |
| p.X61C | ESCA | 1 |
| p.P281H | LUAD | 1 |
| p.S87F | SKCM | 1 |
| p.Q379R | LUAD | 1 |
| p.T360I | THYM | 1 |
| p.L230M | BLCA | 1 |
| p.S31F | SKCM | 1 |
| p.D81H | LUAD | 1 |
| p.L85F | BRCA | 1 |
| p.P224L | SKCM | 1 |
| p.S94P | UCEC | 1 |
| p.R367* | LUSC | 1 |
| p.V455M | STAD | 1 |
| p.P87L | SKCM | 1 |
| p.E56* | UCEC | 1 |
| p.P232L | SKCM | 1 |
| p.G262C | LUAD | 1 |
| p.N426H | OV | 1 |
| p.R112* | UCEC | 1 |
| p.L427P | PRAD | 1 |
| p.N523T | UCEC | 1 |
| p.A188S | HNSC | 1 |
| p.T112N | SKCM | 1 |
| p.R439H | COAD | 1 |
| p.Y528C | LUSC | 1 |
| p.E337K | SKCM | 1 |
| p.E329K | SKCM | 1 |
| p.V449I | COAD | 1 |
| Top |
| TissGeneCNV for NR5A2 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for NR5A2 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Top |
| TissGeneNet for NR5A2 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| NR5A2, NCOA3, ILF3, SRC, NR0B2, CTNNB1, NRIP1, BCKDK, UBE2I, ALB, HNF1A, FTH1, SMARCD3, CYP19A1, PROX1, EDF1, PNRC1, NPPA, CYP7A1, ADIPOQ, ABCC3 (tumor) | NR5A2, NCOA3, ILF3, SUMO1, CTNNB1, COPS5, NRIP1, POLR2D, BCKDK, UBE2I, ALB, PPARGC1A, CYP19A1, PROX1, EDF1, PNRC2, PNRC1, GPS2, CYP7A1, ADIPOQ, ABCC3 (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| NR5A2, HNF4A, ILF3, SRC, NR0B2, SUMO1, CTNNB1, NRIP1, POLR2D, UBE2I, HNF1A, FTH1, PPARGC1A, SMARCD3, EDF1, PNRC2, PNRC1, NPPA, GPS2, CYP7A1, ABCC3 (tumor) | NR5A2, NCOA3, HNF4A, ILF3, SRC, NR0B2, SUMO1, CTNNB1, COPS5, NRIP1, POLR2D, UBE2I, HNF1A, FTH1, PPARGC1A, CYP19A1, EDF1, PNRC2, NPPA, CYP7A1, ABCC3 (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| NR5A2, NCOA3, HNF4A, ILF3, SRC, NRIP1, POLR2D, BCKDK, UBE2I, FTH1, PPARGC1A, SMARCD3, CYP19A1, PROX1, PNRC2, PNRC1, NPPA, GPS2, CYP7A1, ADIPOQ, ABCC3 (tumor) | NR5A2, NCOA3, HNF4A, SUMO1, CTNNB1, COPS5, NRIP1, POLR2D, BCKDK, UBE2I, FTH1, PPARGC1A, SMARCD3, CYP19A1, PROX1, EDF1, PNRC2, PNRC1, GPS2, CYP7A1, ADIPOQ (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| NR5A2, NCOA3, HNF4A, ILF3, SRC, NR0B2, SUMO1, CTNNB1, COPS5, POLR2D, BCKDK, UBE2I, ALB, HNF1A, FTH1, PROX1, EDF1, PNRC2, GPS2, CYP7A1, ABCC3 (tumor) | NR5A2, ILF3, NR0B2, CTNNB1, NRIP1, POLR2D, BCKDK, ALB, HNF1A, PPARGC1A, SMARCD3, CYP19A1, PROX1, EDF1, PNRC2, PNRC1, NPPA, GPS2, CYP7A1, ADIPOQ, ABCC3 (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| NR5A2, NCOA3, HNF4A, ILF3, SRC, NR0B2, SUMO1, CTNNB1, COPS5, NRIP1, POLR2D, UBE2I, ALB, HNF1A, FTH1, SMARCD3, PROX1, PNRC2, PNRC1, GPS2, CYP7A1 (tumor) | NR5A2, NCOA3, HNF4A, SRC, NR0B2, CTNNB1, COPS5, NRIP1, POLR2D, BCKDK, UBE2I, FTH1, PPARGC1A, SMARCD3, PROX1, EDF1, PNRC2, PNRC1, GPS2, CYP7A1, ABCC3 (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| NR5A2, HNF4A, ILF3, SRC, SUMO1, CTNNB1, NRIP1, POLR2D, UBE2I, ALB, HNF1A, FTH1, PPARGC1A, SMARCD3, CYP19A1, PROX1, EDF1, PNRC2, NPPA, CYP7A1, ABCC3 (tumor) | NR5A2, NCOA3, HNF4A, ILF3, NR0B2, SUMO1, CTNNB1, NRIP1, POLR2D, BCKDK, HNF1A, PPARGC1A, SMARCD3, CYP19A1, PROX1, EDF1, PNRC2, PNRC1, GPS2, CYP7A1, ABCC3 (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| NR5A2, ILF3, SRC, NR0B2, CTNNB1, NRIP1, POLR2D, BCKDK, ALB, HNF1A, FTH1, PPARGC1A, SMARCD3, CYP19A1, PROX1, EDF1, PNRC2, PNRC1, GPS2, CYP7A1, ADIPOQ (tumor) | NR5A2, NCOA3, HNF4A, ILF3, NR0B2, SUMO1, COPS5, NRIP1, BCKDK, UBE2I, ALB, HNF1A, FTH1, PPARGC1A, CYP19A1, PROX1, EDF1, GPS2, CYP7A1, ADIPOQ, ABCC3 (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| NR5A2, HNF4A, ILF3, SRC, NR0B2, SUMO1, CTNNB1, COPS5, POLR2D, HNF1A, FTH1, CYP19A1, PROX1, EDF1, PNRC2, PNRC1, NPPA, GPS2, CYP7A1, ADIPOQ, ABCC3 (tumor) | NR5A2, NCOA3, HNF4A, ILF3, NR0B2, SUMO1, CTNNB1, COPS5, NRIP1, POLR2D, BCKDK, UBE2I, ALB, PPARGC1A, CYP19A1, PROX1, EDF1, PNRC2, PNRC1, GPS2, CYP7A1 (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| NR5A2, NCOA3, HNF4A, ILF3, SRC, NR0B2, SUMO1, CTNNB1, NRIP1, POLR2D, FTH1, PPARGC1A, CYP19A1, PROX1, EDF1, PNRC2, PNRC1, NPPA, GPS2, ADIPOQ, ABCC3 (tumor) | NR5A2, HNF4A, ILF3, SRC, NR0B2, SUMO1, CTNNB1, COPS5, NRIP1, POLR2D, UBE2I, PPARGC1A, SMARCD3, CYP19A1, PROX1, EDF1, PNRC2, PNRC1, NPPA, GPS2, CYP7A1 (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| NR5A2, NCOA3, HNF4A, ILF3, SRC, NR0B2, SUMO1, CTNNB1, COPS5, NRIP1, POLR2D, BCKDK, UBE2I, FTH1, PPARGC1A, SMARCD3, CYP19A1, PROX1, EDF1, GPS2, ABCC3 (tumor) | NR5A2, NCOA3, ILF3, SRC, SUMO1, CTNNB1, COPS5, NRIP1, BCKDK, UBE2I, HNF1A, FTH1, PPARGC1A, SMARCD3, CYP19A1, PROX1, EDF1, NPPA, GPS2, CYP7A1, ABCC3 (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| NR5A2, NCOA3, HNF4A, ILF3, SRC, NR0B2, CTNNB1, NRIP1, POLR2D, HNF1A, PPARGC1A, SMARCD3, PROX1, EDF1, PNRC2, PNRC1, NPPA, GPS2, CYP7A1, ADIPOQ, ABCC3 (tumor) | NR5A2, NCOA3, HNF4A, SRC, NR0B2, CTNNB1, COPS5, NRIP1, BCKDK, UBE2I, ALB, HNF1A, PPARGC1A, SMARCD3, PROX1, PNRC2, PNRC1, NPPA, GPS2, CYP7A1, ABCC3 (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| NR5A2, NCOA3, ILF3, NR0B2, SUMO1, COPS5, NRIP1, POLR2D, UBE2I, ALB, HNF1A, FTH1, PPARGC1A, SMARCD3, CYP19A1, PROX1, PNRC2, NPPA, CYP7A1, ADIPOQ, ABCC3 (tumor) | NR5A2, NCOA3, SRC, SUMO1, CTNNB1, COPS5, BCKDK, UBE2I, HNF1A, FTH1, PPARGC1A, SMARCD3, CYP19A1, PROX1, EDF1, PNRC2, PNRC1, GPS2, CYP7A1, ADIPOQ, ABCC3 (normal) |
 |  |
| Top |
| TissGeneProg for NR5A2 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for NR5A2 |
| TissGeneDrug for NR5A2 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for NR5A2 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0006142 | Malignant neoplasm of breast | 12 | BeFree |
| umls:C0678222 | Breast Carcinoma | 12 | BeFree |
| umls:C0346647 | Malignant neoplasm of pancreas | 7 | BeFree,GAD,GWASCAT |
| umls:C0235974 | Pancreatic carcinoma | 6 | BeFree |
| umls:C0596263 | Carcinogenesis | 4 | BeFree |
| umls:C0178874 | Tumor Progression | 3 | BeFree |
| umls:C0007102 | Malignant tumor of colon | 2 | BeFree |
| umls:C0009324 | Ulcerative Colitis | 2 | BeFree,GWASCAT |
| umls:C0021841 | Intestinal Neoplasms | 2 | BeFree |
| umls:C0027627 | Neoplasm Metastasis | 2 | BeFree |
| umls:C0030297 | Pancreatic Neoplasm | 2 | CTD_human,GAD |
| umls:C0699790 | Colon Carcinoma | 2 | BeFree |
| umls:C1458155 | Mammary Neoplasms | 2 | BeFree,LHGDN |
| umls:C0003128 | Anovulation | 1 | CTD_human |
| umls:C0007124 | Noninfiltrating Intraductal Carcinoma | 1 | BeFree |
| umls:C0009402 | Colorectal Carcinoma | 1 | BeFree |
| umls:C0009404 | Colorectal Neoplasms | 1 | BeFree |
| umls:C0010346 | Crohn Disease | 1 | BeFree |
| umls:C0014170 | Endometrial Neoplasms | 1 | LHGDN |
| umls:C0018133 | Graft-vs-Host Disease | 1 | BeFree |
| umls:C0019163 | Hepatitis B | 1 | BeFree,LHGDN |
| umls:C0021361 | Female infertility | 1 | CTD_human |
| umls:C0021367 | Mammary Ductal Carcinoma | 1 | BeFree |
| umls:C0021390 | Inflammatory Bowel Diseases | 1 | BeFree |
| umls:C0023418 | leukemia | 1 | LHGDN |
| umls:C0023470 | Myeloid Leukemia | 1 | BeFree |
| umls:C0023473 | Myeloid Leukemia, Chronic | 1 | BeFree |
| umls:C0024623 | Malignant neoplasm of stomach | 1 | BeFree |
| umls:C0029456 | Osteoporosis | 1 | GAD |
| umls:C0029463 | Osteosarcoma | 1 | BeFree |
| umls:C0038356 | Stomach Neoplasms | 1 | LHGDN |
| umls:C0040336 | Tobacco Use Disorder | 1 | GAD |
| umls:C0206659 | Embryonal Carcinoma | 1 | BeFree |
| umls:C0206701 | Cystadenocarcinoma, Serous | 1 | BeFree |
| umls:C0346627 | Intestinal Cancer | 1 | BeFree |
| umls:C0585442 | Osteosarcoma of bone | 1 | BeFree |
| umls:C0686619 | Secondary malignant neoplasm of lymph node | 1 | BeFree |
| umls:C0699791 | Stomach Carcinoma | 1 | BeFree |
| umls:C0853879 | Invasive breast carcinoma | 1 | BeFree |
| umls:C0858252 | Breast adenocarcinoma | 1 | BeFree |
| umls:C1134719 | Invasive Ductal Breast Carcinoma | 1 | BeFree |
| umls:C1260954 | Morphologically altered structure | 1 | BeFree |
| umls:C1527249 | Colorectal Cancer | 1 | BeFree |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |